Patient
MF-RELAPSED-001 · Algorithm: ALGO-MF-SEZARY-2L
Clinical significance of mutations (ESCAT)
Tumor-board context — the engine does not use these tiers to rank tracks
| Biomarker | Variant | ESCAT | Evidence | Clinical significance | Drugs | Sources |
|---|
| No clinically actionable variants matched in this profile. |
| Biomarker | Status |
|---|
| BIO-CD30-IHC | Excluded (negative) |
Primary current-line option
- Indication
- IND-MF-ADVANCED-2L-BEXAROTENE
- Regimen
- Bexarotene PO monotherapy for CTCL (300 mg/m² daily, continuous)
- Drugs + NSZU
- Bexarotene (DRUG-BEXAROTENE) 300 mg/m² PO once daily with meal · PO daily, continuous; reduce to 200 mg/m² if Grade ≥3 toxicity · PO ✗ Not registered in UA
- Reason
- Primary current-line option selected by ALGO-MF-SEZARY-2L at step 3.
Other current-line alternatives (3 tracks)
Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.
- Indication
- IND-MF-MAINTENANCE-RETINOID
- Regimen
- Bexarotene low-dose maintenance for CTCL responders (75-150 mg/m² PO daily)
- Drugs + NSZU
- Bexarotene (DRUG-BEXAROTENE) 75-150 mg/m² PO once daily with meal (titrate from initial 150 down based on tolerance) · PO daily, indefinite while in response · PO ✗ Not registered in UA
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-MF-ADVANCED-1L-BV
- Regimen
- Brentuximab vedotin monotherapy for CD30+ MF/cutaneous ALCL (1.8 mg/kg IV q3 weeks)
- Drugs + NSZU
- Brentuximab vedotin (DRUG-BRENTUXIMAB-VEDOTIN) 1.8 mg/kg (max 180 mg) · IV over 30 min every 21 days × up to 16 cycles or progression / toxicity · IV ✓ NSZU covered
- Hard contraindications
- CI-BORTEZOMIB-SEVERE-NEUROPATHY
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-MF-ADVANCED-1L-MOGA
- Regimen
- Mogamulizumab monotherapy (1.0 mg/kg IV weekly × 5, then q2 weeks)
- Drugs + NSZU
- Mogamulizumab (DRUG-MOGAMULIZUMAB) 1.0 mg/kg · IV over ≥1h weekly × 5 (induction); then every 2 weeks until progression or toxicity · IV ✗ Not registered in UA
- Reason
- Current-line alternative presented for HCP consideration
Pre-treatment investigations
Investigations before treatment start · critical / standard / desired · merged across tracks
| ID | Name | Priority | Category | Where to order | Needed for |
|---|
| TEST-CBC | Complete Blood Count with Differential | Critical | lab | — | all tracks |
| TEST-CD20-IHC | CD20 Immunohistochemistry | Critical | histology | CSD Lab ✓ (code TBC) | all tracks |
| TEST-CMP | Comprehensive Metabolic Panel | Critical | lab | — | all tracks |
| TEST-FLOW-CYTOMETRY | Flow Cytometry | Critical | histology | CSD Lab ✓ (code TBC) | all tracks |
| TEST-HBV-SEROLOGY | Hepatitis B Serology Panel (HBsAg, anti-HBc total, anti-HBs) | Critical | lab | — | all tracks |
| TEST-HCV-ANTIBODY | HCV Antibody | Critical | lab | — | all tracks |
| TEST-HIV-SEROLOGY | HIV Antibody/Antigen | Critical | lab | — | all tracks |
| TEST-LDH | Lactate Dehydrogenase | Critical | lab | — | all tracks |
| TEST-LFT | Liver Function Tests (ALT, AST, bilirubin, ALP, GGT, albumin) | Critical | lab | — | all tracks |
| TEST-PREGNANCY | Beta-HCG | Critical | lab | — | standard |
| TEST-ECHO | Echocardiography | Standard | imaging | — | aggressive |
| TEST-PET-CT | FDG PET/CT (whole body) | Standard | imaging | — | all tracks |
| TEST-SEZARY-COUNT | Sézary cell count | Standard | lab | CSD Lab ✓ (code TBC) | all tracks |
| TEST-TCR-CLONALITY | TCR clonality | Standard | molecular | CSD Lab ✓ (code TBC) | all tracks |
Red flags — PRO / CONTRA aggressive
PRO-AGGRESSIVE
Triggers that push toward the aggressive track
- MF with large-cell transformation (LCT — ≥25% large cells on biopsy review) — aggressive variant; mandates systemic therapy reassessment, brentuximab vedotin if CD30+
LCT prognosis dismal (median OS 2-4y from LCT). CD30+ subset (~30-50%) → ALCANZA-style brentuximab vedotin monotherapy preferred over chemotherapy. Distinct entity from primary cutaneous ALCL. Skin-directed alone never appropriate post-LCT.
RF-MF-LARGE-CELL-TRANSFORMATIONSRC-NCCN-BCELL-2025SRC-ESMO-CTCL-2024 - Patient has NOT previously received brentuximab vedotin (BV) — eligible for BV-containing first-line and salvage regimens in CD30-expressing diseases: A+AVD in advanced cHL (ECHELON-1, Connors NEJM 2018), BV-CHP in CD30+ PTCL/ALCL (ECHELON-2, Horwitz Lancet 2019), BV monotherapy or BV-containing salvage in R/R cHL (AETHERA post-ASCT consolidation). This eligibility flag is used as an inclusion gate for BV-using algorithm branches; firing means standard BV-route is open. Co-fires with disease-specific CD30-positivity flags.
Inclusion-gate flag (eligibility), not a routing flag — direction "intensify" reflects "BV-route is the preferred first-line where applicable; absence of prior BV does NOT alone trigger BV-using regimen, but it removes the…
RF-PRIOR-BV-NAIVESRC-ECHELON-1-CONNORS-2018SRC-ECHELON-2-HORWITZ-2019SRC-AETHERA-MOSKOWITZ-2015 - T-cell lymphoma with CD30 expression ≥10% by IHC — qualifies for brentuximab vedotin-based regimen (CHP-Bv per ECHELON-2)
ALCL is universally CD30+; PTCL NOS / AITL ~40-60%. Brentuximab replaces vincristine in CHP backbone; ECHELON-2 showed superior outcomes vs standard CHOP. Funding pathway flag — brentuximab not NSZU-reimbursed.
RF-TCELL-CD30-POSITIVESRC-NCCN-BCELL-2025SRC-ESMO-PTCL-2024
CONTRA-AGGRESSIVE
Hard contraindications to escalation
- Severe pre-existing peripheral neuropathy is an absolute contraindication to bortezomib — therapy will likely worsen the neuropathy to a disabling and often permanent extent.CI-BORTEZOMIB-SEVERE-NEUROPATHY
What NOT to do
Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity
Standard plan (IND-MF-ADVANCED-2L-BEXAROTENE)
- Do not start without atorvastatin/fenofibrate prophylaxis — hypertriglyceridemia majoritarily.
- Do not skip baseline + monthly fasting lipids — pancreatitis risk with TG >1000.
- Do not skip baseline + monthly TSH/T4 — central hypothyroidism in 30-50%.
- Do not combine with gemfibrozil — markedly increases bexarotene levels.
- Do not prescribe in pregnant women — Category X teratogenic; effective contraception ≥1 month before/during/after.
- Do not combine with vitamin A supplements — additive toxicity.
- Do not forget about photosensitivity — sun protection counseling.
Standard plan (IND-MF-MAINTENANCE-RETINOID)
- Do not stop abruptly — relapse risk.
- Do not neglect ongoing TG + TSH monitoring — long-term complications even at low dose.
- Do not neglect ongoing contraception counseling in women of childbearing potential.
- Do not allow supply gaps — abrupt cessation risks rapid relapse; secure international supply continuity.
- Do not combine with vitamin A supplements.
- Do not forget about skin cancer surveillance in MF pts on retinoid long-term.
Aggressive plan (IND-MF-ADVANCED-1L-BV)
- Do not prescribe without CD30 IHC ≥10% — ALCANZA inclusion criterion; lower expression = lower response.
- Do not use in pre-existing Grade ≥2 peripheral neuropathy — absolute CI.
- Do not combine with bleomycin (lethal pulmonary toxicity).
- Do not skip neuropathy grading every cycle — dose-cumulative MMAE toxicity.
- Do not use >16 cycles without response justification — risk vs benefit reverses.
Standard plan (IND-MF-ADVANCED-1L-MOGA)
- Do not start mogamulizumab if allo-SCT is planned <50 days — severe GVHD risk per FDA black box.
- Do not ignore drug rash — interrupt + dermatology consult; differentiating from progression is critical.
- Do not combine with other immunosuppressants without dermatology + ID coordination — infection risk elevated.
- Do not use in the absence of MoH-import confirmation or clinical trial — not registered in Ukraine.
- Do not skip Sezary count baseline + repeat q3 mo — primary end point response in B-compartment.
Monitoring schedule
Monitoring schedule by treatment phase
Aggressive plan · MON-MF-SYSTEMIC
| Phase | Window | Tests | Checkpoints |
|---|
| Baseline | Within 2 weeks before first dose | TEST-CBC, TEST-CMP, TEST-LFT, TEST-LDH, TEST-SEZARY-COUNT, TEST-TCR-CLONALITY, TEST-FLOW-CYTOMETRY, TEST-CD20-IHC, TEST-HBV-SEROLOGY, TEST-HCV-ANTIBODY, TEST-HIV-SEROLOGY, TEST-PET-CT | - Confirm TNMB stage; document T/N/M/B + IA-IVB stage
- Skin photograph baseline (mSWAT score) for response tracking
- If allo-SCT planned downstream — defer mogamulizumab (severe GVHD risk per FDA black box)
- Dermatology partnership for AE management (mogamulizumab rash ~25%)
|
| Induction | Weekly × 5 doses (mogamulizumab) OR every 3 weeks (BV-mono) | TEST-CBC, TEST-CMP | - Infusion reactions (especially mogamulizumab first dose)
- Skin AE grading (CTCAE) — interrupt if severe rash; differentiate drug rash from disease progression
|
| Maintenance | Every 2 weeks (mogamulizumab) OR every 3 weeks (BV-mono) until progression / toxicity | TEST-CBC, TEST-CMP, TEST-LFT | - mSWAT skin response every 2-3 months
- Sézary count repeat at 3 months (mogamulizumab — blood compartment response)
- Neuropathy grading on BV-mono
|
| Response assessment | After 12-16 weeks of therapy | TEST-PET-CT, TEST-SEZARY-COUNT | - Global response per ISCL/EORTC consensus (skin + nodes + viscera + blood)
- Continue if responding; switch line if stable/progressive
|
| Follow-up | Every 3 months × 2 years post-treatment, then every 6 months | TEST-CBC, TEST-LFT, TEST-LDH, TEST-SEZARY-COUNT | - Surveillance for relapse + LCT
- Skin cancer screening (CTCL + treatment increases risk)
|
Timeline
Treatment timeline — derived from regimen + monitoring schedule
Standard plan
Induction · Bexarotene PO monotherapy for CTCL (300 mg/m² daily, continuous)
28-day cycles × Continuous until progression / unacceptable toxicity; can transition to maintenance dose 75-150 mg/m²
Standard plan
Induction · Bexarotene low-dose maintenance for CTCL responders (75-150 mg/m² PO daily)
28-day cycles × Indefinite — continue while in response and tolerable
Aggressive plan
Baseline
Within 2 weeks before first dose
Induction · Brentuximab vedotin monotherapy for CD30+ MF/cutaneous ALCL (1.8 mg/kg IV q3 weeks)
21-day cycles × Up to 16 (per ALCANZA); shorter if CR or limiting toxicity
Response assessment
After 12-16 weeks of therapy
Maintenance
Every 2 weeks (mogamulizumab) OR every 3 weeks (BV-mono) until progression / toxicity
Follow-up
Every 3 months × 2 years post-treatment, then every 6 months
Standard plan
Baseline
Within 2 weeks before first dose
Induction · Mogamulizumab monotherapy (1.0 mg/kg IV weekly × 5, then q2 weeks)
14-day cycles × 5 weekly induction + maintenance until progression / toxicity
Response assessment
After 12-16 weeks of therapy
Maintenance
Every 2 weeks (mogamulizumab) OR every 3 weeks (BV-mono) until progression / toxicity
Follow-up
Every 3 months × 2 years post-treatment, then every 6 months
MDT brief
Discussion questions (4, 2 blocking)
BLOCKING OQ-HBV-SEROLOGY
Has HBV serology (HBsAg, anti-HBc total) been done? Status must be known before starting anti-CD20 therapy.
Anti-CD20 without HBV prophylaxis in HBsAg+/anti-HBc+ patients carries significant reactivation risk (CI-HBV-NO-PROPHYLAXIS).
→ infectious_disease_hepatology
BLOCKING OQ-CD20-CONFIRMATION
Is CD20+ status confirmed by histology (IHC)? Without CD20+, rituximab/obinutuzumab are not indicated.
Anti-CD20 therapy is the backbone of most lines of treatment; absence of CD20 expression fully changes the regimen.
→ pathologist
OQ-STAGING-COMPLETE
Has complete staging been done (Lugano + PET/CT or CT)?
Prognosis and track selection depend on stage and tumor burden.
→ radiologist
OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
MDT talk tree (5 steps)
| # | Owner | Topic | Action |
|---|
| 1 | infectious_disease_hepatology | Infection / hepatic safety BLOCKING | Has HBV serology (HBsAg, anti-HBc total) been done? Status must be known before starting anti-CD20 therapy. |
| 2 | pathologist | Pathology confirmation BLOCKING | Is CD20+ status confirmed by histology (IHC)? Without CD20+, rituximab/obinutuzumab are not indicated. |
| 3 | hematologist | Staging / disease burden | What is the current LDH? Marker of tumor burden and transformation. |
| 4 | radiologist | Staging / disease burden | Has complete staging been done (Lugano + PET/CT or CT)? |
| 5 | clinical_pharmacist | Specialist review | Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication. |
Skills (required) — mandatory virtual specialists (1)
Skills (recommended) — for consideration (2)
- Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
- Pathologist (general) recommended
Confirm lymphoma histology + assess transformation risk (DLBCL/Richter).
Owns: OQ-CD20-CONFIRMATION
Data quality
Incomplete for MDT sign-off. MDT sign-off is incomplete until critical clinical data gaps are resolved.
- Biomarker coverage: 1/1 known (100%), 0 missing, 0 default-track gaps
- Missing critical: cd20_ihc_status, hbsag blocks: RF-MF-SEZARY-INFECTION-SCREENING, anti_hbc_total blocks: RF-MF-SEZARY-INFECTION-SCREENING, lugano_stage
- Missing recommended: ldh_ratio_to_uln, fib4_index, pet_ct_date
- Unevaluated RedFlags: RF-MF-LARGE-CELL-TRANSFORMATION, RF-MF-SEZARY-FRAILTY-AGE, RF-MF-SEZARY-INFECTION-SCREENING, RF-MF-SEZARY-LEUKEMIC, RF-MF-SEZARY-ORGAN-DYSFUNCTION
Missing data for doctor action
| Priority | Clinical item | Owner | Why it matters | Next action | Blocks |
|---|
| CRITICAL | CD20 IHC status cd20_ihc_status
| pathologist | Confirms CD20-directed therapy is biologically appropriate. | Verify CD20 IHC result, specimen, method, and report date. | - |
| CRITICAL | HBsAg hbsag
| infectious_disease_hepatology | Identifies active HBV infection and prophylaxis need before anti-CD20 or other immunosuppressive therapy. | Order or document HBsAg before treatment start. | RF-MF-SEZARY-INFECTION-SCREENING |
| CRITICAL | Total anti-HBc anti_hbc_total
| infectious_disease_hepatology | Detects prior HBV exposure and reactivation risk. | Order or document total anti-HBc and decide prophylaxis/monitoring. | RF-MF-SEZARY-INFECTION-SCREENING |
| CRITICAL | Lugano stage lugano_stage
| radiologist | Defines lymphoma extent and supports tumor-burden and response-assessment decisions. | Document Lugano stage from PET/CT or contrast CT staging. | - |
| RECOMMENDED | LDH ratio to ULN ldh_ratio_to_uln
| medical_oncologist | Supports prognostic scoring and aggressive-biology flags. | Enter LDH with local upper limit of normal. | - |
| RECOMMENDED | FIB-4 liver fibrosis index fib4_index
| infectious_disease_hepatology | Screens hepatic fibrosis risk before hepatotoxic therapy or antiviral coordination. | Calculate FIB-4 from age, AST, ALT, and platelet count. | - |
| RECOMMENDED | PET/CT date pet_ct_date
| radiologist | Shows whether baseline staging is recent enough for treatment planning and later response comparison. | Document baseline PET/CT date or explain alternative staging modality. | - |
Technical MDT skill metadata (3/16 activated in this plan)
All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
| Specialist | skill_id | Version | Last reviewed | Sign-offs | Domain |
|---|
| Cellular therapy specialist (CAR-T) | cellular_therapy_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
| Clinical pharmacist | clinical_pharmacist | v0.1.0 | 2026-04-25 | 0 | clinical_pharmacy |
| Hematologist / oncohematologist | hematologist | v0.1.0 | 2026-04-25 | 0 | hematology_oncology |
| Hematopathologist (lymphoma / leukemia / myeloma) | hematopathologist | v0.1.0 | 2026-04-25 | 0 | hematopathology |
| Infectious disease / hepatology | infectious_disease_hepatology | v0.1.0 | 2026-04-25 | 0 | infectious_diseases |
| Medical oncologist (solid-tumor chemotherapist) | medical_oncologist | v0.1.0 | 2026-04-25 | 0 | solid_oncology |
| Molecular geneticist / molecular oncologist | molecular_geneticist | v0.1.0 | 2026-04-25 | 0 | molecular_oncology |
| Palliative care | palliative_care | v0.1.0 | 2026-04-25 | 0 | palliative_care |
| Pathologist (general) | pathologist | v0.1.0 | 2026-04-25 | 0 | pathology |
| Primary care / family physician | primary_care | v0.1.0 | 2026-04-25 | 0 | primary_care |
| Psycho-oncologist | psychologist | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Radiation oncologist | radiation_oncologist | v0.1.0 | 2026-04-25 | 0 | radiation_oncology |
| Radiologist | radiologist | v0.1.0 | 2026-04-25 | 0 | diagnostic_imaging |
| Social worker / case manager | social_worker_case_manager | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Surgical oncologist | surgical_oncologist | v0.1.0 | 2026-04-25 | 0 | surgical_oncology |
| Transplant specialist (BMT) | transplant_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
Sources cited
- SRC-ESMO-CTCL-2024: ESMO Clinical Practice Guideline on Primary Cutaneous Lymphomas (CTCL — MF / Sézary syndrome) (2024)
- SRC-NCCN-BCELL-2025: NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas (v.2.2025)
Experimental options (clinical trials)
Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-07-26.
| NCT | Title | Phase | Status | Sponsor | UA | Signals | Eligibility (excerpt) |
|---|
| NCT04904146 | Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. | N/A | RECRUITING | — | Single country | |
| NCT06382844 | Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL | N/A | RECRUITING | — | Single country | |
| NCT06588868 | Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma | N/A | RECRUITING | — | Single country | |
| NCT04256018 | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | PHASE2 | RECRUITING | — | Small N (<50) Surrogate endpoint only Single country | |
| NCT02848274 | ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | N/A | RECRUITING | — | — | |
| NCT07003100 | A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | N/A | RECRUITING | — | Single country | |
| NCT05996185 | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | PHASE2 | RECRUITING | — | Small N (<50) Single country | |
| NCT04234048 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | PHASE1 | RECRUITING | — | Phase 1 only Small N (<50) Single country | |
Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.
Option availability in Ukraine
Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).
| Option | UA registration | NSZU | Cost orientation | Access pathway |
|---|
| Standard plan Bexarotene PO monotherapy for CTCL (300 mg/m² daily, continuous) (REG-BEXAROTENE-MONO-CTCL) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Standard plan Bexarotene low-dose maintenance for CTCL responders (75-150 mg/m² PO daily) (REG-BEXAROTENE-MAINTENANCE-CTCL) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Aggressive plan Brentuximab vedotin monotherapy for CD30+ MF/cutaneous ALCL (1.8 mg/kg IV q3 weeks) (REG-BV-MONO-MF) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Standard plan Mogamulizumab monotherapy (1.0 mg/kg IV weekly × 5, then q2 weeks) (REG-MOGAMULIZUMAB) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Trial · NCT04904146 Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06382844 Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06588868 Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT04256018 Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT02848274 ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07003100 A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05996185 Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT04234048 Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-07-26.